Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Aldeyra Therapeutics' stock plunges 75% as FDA demands more trials for its dry eye drug, reproxalap.
Aldeyra Therapeutics' stock fell by 75% after the FDA issued a Complete Response Letter for its dry eye disease drug, reproxalap, citing concerns over trial data.
The FDA requires additional studies to demonstrate the drug's efficacy.
The biotech company is now under investigation for potential securities law violations.
Aldeyra plans to release more trial data in the second quarter and resubmit the drug application later this year.
11 Articles
El stock de Aldeyra Therapeutics se hunde un 75% mientras la FDA exige más ensayos para su medicamento para los ojos secos, el reproxalap.